Toll-like receptor 3 ligand and retinoic acid enhance germinal center formation and increase the tetanus toxoid vaccine response.
Immunizations with T-cell-dependent antigens induce the formation of germinal centers (GC), unique lymphoid microenvironments in which antigen-activated B cells undergo class switching, affinity maturation, and differentiation into memory B cells. Poly(I:C) (PIC), a double-stranded RNA, and retinoic acid (RA), a metabolite of vitamin A which induces cell differentiation, have been shown to augment both primary and memory anti-tetanus toxoid (anti-TT) IgG responses. However, their influence on the GC reaction is unknown. In the present study, 6-week-old C57BL/6 mice were immunized with TT and cotreated with PIC, RA, or both. The splenic GC reaction was evaluated using immunofluorescence staining 10 days after TT priming. Each treatment enhanced the TT-induced GC formation (number of GC/follicle and GC area) about two- to threefold, which correlated with the titers of plasma anti-TT immunoglobulin G (IgG). Isotype switching to IgG1 was dramatically stimulated, with the greatest increase in IgG1-positive GC B cells induced by RA-PIC (P < 0.001). Moreover, PIC alone and RA-PIC robustly promoted the formation of the follicular dendritic cell (FDC) network in the GC light zone. PIC and RA-PIC also increased IgG1-positive B cells in the periarterial lymphatic sheath regions, where most IgG1-positive cells were plasma cells (CD138/syndecan-1 positive), suggesting that plasma cell generation was also enhanced in non-GC regions. The stimulation of several processes, including antigen-induced GC formation, isotype switching, FDC network formation within GC, and plasma cell differentiation by RA and/or PIC, suggests that this nutritional-immunological combination could be an effective means of promoting a robust vaccine response.
Ma
Yifan
Y
Department of Nutritional Sciences and Huck Institute for the Life Sciences, Pennsylvania State University, University Park, Pennsylvania 16802, USA.
Ross
A Catharine
AC
D000818:Animals; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D020566:Dendritic Cells, Follicular / Q000187:drug effects / Q000276:immunology; D005260:Female; D018858:Germinal Center / Q000166:cytology / Q000187:drug effects* / Q000276:immunology*; D007074:Immunoglobulin G / Q000096:biosynthesis; D008024:Ligands; D051379:Mice; D008810:Mice, Inbred C57BL; D010950:Plasma Cells / Q000187:drug effects / Q000276:immunology; D011070:Poly I-C / Q000494:pharmacology; D013745:Tetanus Toxoid / Q000494:pharmacology*; D051196:Toll-Like Receptor 3 / Q000378:metabolism*; D014212:Tretinoin / Q000494:pharmacology*
D007074:Immunoglobulin G; D008024:Ligands; C519703:TLR3 protein, mouse; D013745:Tetanus Toxoid; D051196:Toll-Like Receptor 3; D014212:Tretinoin; D011070:Poly I-C
Semin Immunol. 2009 Feb;21(1):42-50
18819820
Semin Hematol. 1994 Oct;31(4 Suppl 5):31-7
7831583
Eur J Immunol. 2006 Apr;36(4):810-6
16541472
J Immunol. 1999 Jul 1;163(1):57-61
10384099
Adv Anat Embryol Cell Biol. 2000;151:III-IX, 1-101
10592524
Science. 2007 Jul 13;317(5835):256-60
17569825
Clin Immunol Immunopathol. 1996 Sep;80(3 Pt 2):S63-72
8811065
Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13556-61
16157890
Blood. 2007 May 1;109(9):3865-72
17209053
Cancer Treat Rep. 1978 Nov;62(11):1907-12
728910
Adv Exp Med Biol. 2007;590:139-48
17191383
Immunology. 2005 Jan;114(1):2-10
15606789
Int Immunopharmacol. 2005 Dec;5(13-14):1830-8
16275619
Curr Opin Immunol. 2005 Jun;17(3):298-302
15886120
J Biol Chem. 2003 Jun 13;278(24):21502-9
12672806
J Clin Immunol. 2007 Jan;27(1):88-94
17216566
Clin Microbiol Rev. 2008 Jan;21(1):13-25
18202435
Science. 2006 Nov 17;314(5802):1157-60
17110582
Proc Nutr Soc. 2000 Nov;59(4):519-29
11115786
Vet Microbiol. 2002 Sep 24;88(4):325-38
12220808
Cell Immunol. 2007 Sep;249(1):37-45
18082674
J Immunol. 2000 Nov 15;165(10):5462-71
11067898
Semin Immunol. 2008 Feb;20(1):14-25
18261920
Immunology. 2006 Aug;118(4):539-48
16780564
Clin Vaccine Immunol. 2006 Aug;13(8):821-9
16893980
J Biol Chem. 1992 Nov 25;267(33):23988-92
1429735
Urol Int. 2004;73(1):47-53
15263793
Curr Opin Immunol. 2007 Jun;19(3):275-80
17433651
J Clin Immunol. 2007 Jul;27(4):363-71
17370119
Immunity. 2004 Oct;21(4):527-38
15485630
J Interferon Res. 1989 Aug;9(4):445-56
2502585
Annu Rev Nutr. 2001;21:167-92
11375434
Eur J Immunol. 2006 Aug;36(8):2013-24
16810634
Lancet. 1986 May 24;1(8491):1169-73
2871418
Br J Haematol. 2003 Sep;122(5):829-36
12930397
Neurosurgery. 1996 Jun;38(6):1096-103; discussion 1103-4
8727138
J Infect Dis. 2000 Sep;182 Suppl 1:S29-36
10944482
Vaccine. 2001 Mar 21;19(17-19):2227-32
11257338
Curr Top Microbiol Immunol. 2006;311:17-58
17048704
Annu Rev Immunol. 2008;26:481-511
18304001
Nature. 2006 Apr 6;440(7085):808-12
16489357
Cell Immunol. 1993 May;148(2):291-300
8495495
Lancet. 2007 Dec 8;370(9603):1947-59
17854885
Immunology. 2001 Nov;104(3):341-8
11722649
Blood. 2004 Dec 15;104(13):4157-64
15315972
Adv Exp Med Biol. 2005;560:11-8
15932016
Adv Drug Deliv Rev. 2008 Apr 29;60(7):805-12
18262679
Clin Microbiol Rev. 2005 Jul;18(3):446-64
16020684
Vitam Horm. 2007;75:197-222
17368317
Immunol Rev. 1992 Apr;126:143-61
1597318
Am J Clin Nutr. 1994 Apr;59(4):922-8
8147339
J Exp Med. 1991 May 1;173(5):1165-75
1902502
J Exp Med. 2007 Aug 6;204(8):1765-74
17620363
Curr Top Microbiol Immunol. 2006;311:59-83
17048705
J Immunol. 2005 Jun 15;174(12):7961-9
15944302
J Exp Med. 2005 Feb 21;201(4):545-54
15710653
J Nutr. 2002 Dec;132(12):3736-9
12468615
Immunol Rev. 2000 Aug;176:181-93
11043777
FASEB J. 1991 Jul;5(10):2473-81
2065894
J Immunol. 2000 Jun 1;164(11):5729-38
10820250
Immunol Lett. 2007 Apr 15;109(2):93-100
17374402
Annu Rev Immunol. 2008;26:261-92
18370922